This article was originally published in The Gray Sheet
In the March 19 issue of "The Gray Sheet," a story incorrectly identified the company led by Jim Mazzo (1"The Gray Sheet" March 19, 2006, p. 3). Mazzo is CEO of Advanced Medical Optics...
You may also be interested in...
It’s The Economy, Stupid: “Value” Campaign To Stress System-Wide Savings
AdvaMed will invest $2 million in 2007 to accelerate its public campaign to underscore the "value" of medical technology to patients, practitioners and policymakers, placing added emphasis on the long-term cost savings devices provide to the U.S. economy
US FDA Complete Response Letter Rates Vary With Sponsor Size
Pink Sheet infographic illustrates benefits of big pharma’s resources and experience.
Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?
Making the Office of Therapeutic Biologics and Biosimilars a stand-alone office in CDER may allow it to add more expertise, but is there an appetite for another reorganization?